MiR-598 has been found to play inhibitory role in osteosarcoma progression in vivo and in vitro by modulating osteoblastic differentiation in the microenvironment and targeting PDGFB and MET. Based on expressed sequence tags (ESTs) resources from the LNCaP cells, Saravanan et al. identified an hsa-miR-3654 with a higher expression level in LNCaP cells than the normal and androgen insensitive prostate cancer cell lines (PNT1A, PC-3) [101]. Here, MET is linked to osteosarcoma.